Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026
Company Deals

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Fineline Cube Mar 4, 2026
Company Deals

Leman Biotech Raises RMB 200M Series A+ – Advances Ultra‑Low‑Dose Metabolically Armored CAR‑T

Fineline Cube Mar 4, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Eli Lilly’s Eloralintide Wins CDE Approval for Phase III Trials in China – Weekly Amylin Agonist Targets Weight Management Market

Fineline Cube Mar 5, 2026
Company Drug

Pyrotech Therapeutics’ PTT-936 Wins NMPA Approval – Novel ALPK1 Agonist Targets Bladder Cancer

Fineline Cube Mar 5, 2026
Company Deals

Degron Therapeutics Secures $20M Series A+ for Molecular Glue Drug Development

Fineline Cube Jan 22, 2025

China-based Degron Therapeutics, a specialist in molecular glue-based drugs, has reportedly raised over USD 20...

Company Drug

FDA Lifts Clinical Hold on Sanofi’s Cialis Over-the-Counter Trial

Fineline Cube Jan 22, 2025

France-based Sanofi’s (NASDAQ: SNY, EPA: SAN) Consumer Healthcare unit Opella has announced that the US...

Company Drug

Johnson & Johnson’s Spravato Approved as Monotherapy for Major Depressive Disorder

Fineline Cube Jan 22, 2025

US-based Johnson & Johnson (J&J; NYSE: JNJ) has announced that its Spravato (esketamine) CIII nasal...

Company Drug

CD Biopharma Initiates Phase I Trial for CD-001 in Advanced Solid Tumors

Fineline Cube Jan 22, 2025

Suzhou-based tumor immunotherapy specialist CD Biopharma has announced the first subject dosing of a Phase...

Company Medical Device

Kehua Bioengineering Gains NMPA Approval for Gene Polymorphism Detection Kits

Fineline Cube Jan 22, 2025

China-based Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022) has announced receiving marketing approvals from the...

Company Drug

Humanwell’s HWH340 Receives Clinical Approval for Prostate Cancer Treatment

Fineline Cube Jan 22, 2025

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that its Class 1 chemical drug...

Company Deals

Sichuan Biokin Re-submits IPO Application to Hong Kong Stock Exchange

Fineline Cube Jan 22, 2025

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has resubmitted its application...

Company Medical Device

Acotec’s Vericor-S2 Coronary Microcatheter Approved by NMPA

Fineline Cube Jan 22, 2025

Acotec Scientific Holdings Ltd (HKG: 6669) has announced that its Vericor-S2 coronary microcatheter has received...

Company Deals

Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent

Fineline Cube Jan 22, 2025

Lepu Biopharma Co., Ltd (HKG: 2157) has announced an exclusive licensing agreement with ArriVent BioPharma,...

Policy / Regulatory

Trump Signs Executive Order to Withdraw from WHO, Drawing Criticism

Fineline Cube Jan 21, 2025

President Donald Trump has signed an executive order indicating the withdrawal of the United States...

Hospital

Douyin Gains Approval to Establish Hospital in Beijing’s Zhongguancun

Fineline Cube Jan 21, 2025

The Beijing Municipal Health Commission has approved Douyin, the Chinese short-form video hosting service owned...

Company Medical Device

NMPA Approves Synaptic Medical’s Cryoablation Device and Gene Methylation Detection Kit

Fineline Cube Jan 21, 2025

China’s National Medical Products Administration (NMPA) has granted marketing approval for two new medical devices:...

Company Drug

Huadong Medicine’s MediBeacon TGFR System Receives FDA Marketing Clearance

Fineline Cube Jan 21, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing clearance from the US...

Company Drug

MediLink’s YL201 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma

Fineline Cube Jan 21, 2025

Suzhou-based biotech MediLink Therapeutics (Suzhou) Co., Ltd has announced receiving another breakthrough therapy designation (BTD)...

Company Drug

Jiangsu Lianhuan Completes Enrollment for Phase III Study of LH-1801 in Type 2 Diabetes

Fineline Cube Jan 21, 2025

China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) has announced the completion of subject enrollment...

Company Drug

Arrowhead’s Plozasiran Accepted for FDA Review in Familial Chylomicronemia Syndrome

Fineline Cube Jan 21, 2025

US-based Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced that the New Drug Application (NDA) for...

Company Deals

Keymed and InnoCare Announce Licensing Deal for CD20xCD3 Bispecific Antibody with Prolium

Fineline Cube Jan 21, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) and InnoCare Pharma (HKG: 9969, SHA: 688428) have jointly...

Company Drug

GSK’s Jemperli Approved for First-Line Endometrial Cancer Treatment in EU

Fineline Cube Jan 21, 2025

UK-based GSK plc (NYSE: GSK, LON: GSK) has announced receiving approval from the European Commission...

Company Drug

Kelun-Biotech’s Tagitanlimab Receives NMPA Clearance for Nasopharyngeal Carcinoma

Fineline Cube Jan 21, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving another clearance from the...

Company Deals

Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets

Fineline Cube Jan 21, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced a licensing agreement...

Posts pagination

1 … 187 188 189 … 630

Recent updates

  • Eli Lilly’s Eloralintide Wins CDE Approval for Phase III Trials in China – Weekly Amylin Agonist Targets Weight Management Market
  • Pyrotech Therapeutics’ PTT-936 Wins NMPA Approval – Novel ALPK1 Agonist Targets Bladder Cancer
  • Konruns Pharma’s KC1036 Wins NMPA Approval – Dual‑Target VEGFR2/AXL Inhibitor Enters IO Combination Trials
  • Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company
  • Sichuan Biokin’s CD33 ADC BL-M11D1 Wins NMPA Approval – Expands into Myelodysplastic Syndromes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Eli Lilly’s Eloralintide Wins CDE Approval for Phase III Trials in China – Weekly Amylin Agonist Targets Weight Management Market

Company Drug

Pyrotech Therapeutics’ PTT-936 Wins NMPA Approval – Novel ALPK1 Agonist Targets Bladder Cancer

Company Drug

Konruns Pharma’s KC1036 Wins NMPA Approval – Dual‑Target VEGFR2/AXL Inhibitor Enters IO Combination Trials

Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.